December 11, 2025 – Hasten Biopharmaceutical Co., Ltd. (“Hasten”) and Everest Medicines (HKEX 1952.HK, "Everest") together announced that Everest’s wholly-owned subsidiary, Everest Medicines (China) Co., Ltd (“Everest Medicines China”), has entered into two strategic agreements with Hasten. The first is a Commercialization Services Agreement leveraging Everest’s existing sales and marketing organization to provide commercialization services for a portfolio of Hasten’s mature assets in Chinese mainland, covering critical care, cardiovascular and metabolism. The second is a License Agreement granting Everest Medicines China the exclusive license to develop, register and commercialize Lerodalcibep in Greater China.

This strategic collaboration represents a pivotal milestone for Hasten in optimizing global resource allocation and deepening its strategic focus on the Asia-Pacific market. By leveraging Everest's proven commercial excellence and robust new drug launch capabilities, the partnership aims to unlock unprecedented strategical synergy and drive sustainable value creation for Hasten's product portfolio in the Chinese mainland market.

In future, Hasten will allocate more resources and focus to the high-potential Pan-Asia Pacific market, accelerating its strategic emphasis and commercial network development in the region to enhance the accessibility of high-quality medications across a broader area.